openPR Logo
Press release

STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics

12-12-2017 12:17 PM CET | Science & Education

Press release from: SMi Group

STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics

SMi are delighted to welcome Oliver Rausch, VP Research & Development, Storm Therapeutics, onto the speaker line-up for day 1 at RNA Therapeutics 2018!

Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM and subsequently joined the company full time in October 2016.

Prior to STORM, Oliver was Programme Director at the National Institute for Health Research (NIHR), where he led the Translational Research Partnerships (TRPs) initiative and other industry-focused collaboration programmes in experimental medicine and early drug development. He served as Vice President Biology at Cellzome until the company’s acquisition by GSK in 2012, and as Director of Biology at UCB Pharma until 2008.

SMi are excited to have interviewed Oliver about his talk and career experience.

Below is a snapshot of his interview:

Q. What do you see as the greatest challenge for those trying to develop RNA Therapeutics?

A. Delivery of the therapeutic molecules to the appropriate target tissues – there are limitations for RNA therapies which we are trying to overcome through a small molecule approach.

Q. What is the most exciting project that you have worked on during your career and why?

A. The project of setting up and launching Storm Therapeutics, establishing a drug discovery organisation in a completely untapped field of biology.

Q. Are there any dangers associated with the use of RNA modifying enzymes?

Check out the full interview, available in the download centre.

Hear more from Oliver Rausch at RNA Therapeutics this February 2018, as he presents 'Harnessing the Power of RNA Epigenetics - Targeting RNA Modifying Enzymes for the Treatment of Cancer.' www.therapeutics-rna.com/opr

Topics will explore:

- Over 150 different chemical modifications have been identified on RNA molecules.
- The role of these modifications in the maturation and regulation of coding and non-coding RNA is becoming increasingly prominent.
- Utilising the research of world-leading founders Professors Kouzarides and Miska in the field of RNA epigenetics to pioneer the development of small molecule inhibitors of previously untargeted RNA-modifying enzymes (RMEs) to interfere with key RNA pathways and mechanisms.

More About Oliver Rausch:

Oliver has over 15 years’ drug discovery experience in inflammation, neurology and oncology. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.

Further information is available at: www.therapeutics-rna.com/opr

SMi presents the 9th Annual Conference:

RNA Therapeutics
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Website: www.therapeutics-rna.com/opr

Sponsored by: ChemGenes | Phion Therapeutics | Advanced Cell Diagnostics | Lypocalyx

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Westminster Bridge Road
1

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics here

News-ID: 856447 • Views: 399

More Releases from SMi Group

Invitation from Conference Chairman, Jeremy Heath, Sutton & East Surrey Water fo …
Building on the success of previous years, SMi’s 11th Annual Smart Water Systems Conference will offer peer-to-peer networking with leaders in the Smart Water Market give delegates in depth knowledge on the requirements you need to build an efficient Advanced Metering Infrastructure. The conference will convene on 4th and 5th April 2022 in London, UK, interested parties can register at http://www.smart-water-systems.com/PR2openPR - register by 31st January 2022 to save £200. The aim
New speakers from Abbvie, GSK, Scripps Research and Engitix Therapeutics join 3D …
SMi Group reports: new speakers from Abbvie, GSK, Scripps Research and Engitix Therapeutics join the 5th Annual 3D Cell Culture Conference in February 2022 Only four weeks to go until the 5th Annual 3D Cell Culture will now take place as a ‘Virtual Conference’ with online access only on 9th and 10th February 2022. Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to
Registration is now open for Highly Potent Active Pharmaceutical Ingredients 202 …
SMi Group reports: The 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference is set to return in May 2022 with a focus on key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies. SMi Group is delighted to announce the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference, taking place on the 9th and 10th May 2022 in London, UK. The 2022 Conference theme is ensuring product quality
Book to attend the Parallel Trade conference before midnight Friday 28th January …
SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. The 2022 event will be more significant than ever before due to the transition period after Brexit coming to an

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
DNA/RNA Extraction Equipment Market: Competitive Dynamics & Global Outlook 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global DNA/RNA Extraction Equipment market. Robotic liquid handling technology in automated DNA extraction systems can streamline the tasks involved in extracting DNA from a sample, such as serial dilution and cherry picking. Systems typically also include functions such as shaking, temperature control, and PCR protocols. DNA extraction is used in many types of biological research including molecular
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and